CytoDyn, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cytodyn.com
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03838367
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸CD07 Investigational Site, Chicago, Illinois, United States
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02990858
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 556
- Registration Number
- NCT02859961
- Locations
- 🇺🇸
CD03 Investigational site, Syracuse, New York, United States
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
- Conditions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT02759042
- Locations
- 🇺🇸
CD02 EA Investigational site, Orlando, Florida, United States
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02737306
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Loyola University Medical Center Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸West Virginia University Medicine, Morgantown, West Virginia, United States
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
- Conditions
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02483078
- Locations
- 🇺🇸
E Study Site, Las Vegas, Nevada, United States
🇵🇷CD02 Investigational site, San Juan, Puerto Rico
🇺🇸CD02 Investigational Site, Spokane, Washington, United States
An Extension of Protocol PRO 140_CD01 TS Study
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02355184
- Locations
- 🇺🇸
CD01-Extension Investigational Site, San Francisco, California, United States
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02175680
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT01272258
- Locations
- 🇺🇸
Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
Observational Study of Blood Treated With Cytolin
- Conditions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01048372
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States